FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1694-1695 November 25, 1999 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

The recent report by Schenk et al.¹ raises the hope of a vaccine for Alzheimer's disease. This report has justifiably received wide attention in both the scientific and lay media. It describes an initial study in transgenic mice, which had been developed as an animal model to test potential treatments for Alzheimer's disease.

Scientifically, the paper is straightforward and impressive. The authors studied transgenic mice that overexpress a mutant form of the human amyloid precursor protein. The cerebral amyloidosis that develops in these animals is similar to that in the brains of patients with Alzheimer's disease.¹ Cerebral amyloidosis was largely . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.